+ Site Statistics
References:
52,572,879
Abstracts:
28,705,754
PMIDs:
27,750,366
DOIs:
25,464,004
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The role of dobutamine stress echocardiography in early diagnosis of cardiac toxicity in long-term survivors of asymptomatic children treated with anthracycline



The role of dobutamine stress echocardiography in early diagnosis of cardiac toxicity in long-term survivors of asymptomatic children treated with anthracycline



Anadolu Kardiyoloji Dergisi 10(2): 154-162



Long-term survivors of asymptomatic children treated with anthracycline may have cardiac toxicity without clinical findings. The subclinical cardiac toxicity could be evaluated by dobutamine stress echocardiography (DSE) with exploring effective and safe doses of dobutamine. Twenty asymptomatic survivors (mean age: 19.2+/-4.0 years) treated with cumulative dose of 282.1+/-125.9 mg/m2 of anthracycline were compared with 18 age-matched healthy volunteers. Total time completed this treatment was 10.2+/-2.2 years. This was a cross-sectional case-controlled study and patient and control groups were evaluated at the time of routine appointments. Echocardiographic studies were performed before and after each dobutamine infusion of 5, 10, 15, 20 microg/kg/min. Mann-Whitney U test was used to evaluate the difference between the groups. ANOVA for repeated measurements test was used to compare each measurement of control and patients groups and Bonferroni posthoc test was used for correction. Hemodynamic changes are observed at the dobutamine doses of 15 microg/kg/min in the patient group. Before dobutamine infusion in the patient group only isovolumic relaxation and contraction times values were prolonged comparing to the control group. After the infusion of dobutamine ejection fraction, shortening fraction, left ventricular posterior wall thickening (%LVPWt), end-systolic wall stress (ESS), interventricular septum systolic thickening, left ventricular end-systolic and end-diastolic diameters, mitral acceleration (AT) and deceleration times values were deteriorated in the patient group compared to the control group (p=0.05 for all). The highest differences between the groups were observed in the %LVPWt, ESS and AT values at the end of test. The DSE is an effective and safe method to demonstrate the late anthracycline cardiotoxicity. Echocardiographic evaluation should be made at rest and dobutamine dose of 20 microg/kg/min. In the early diagnosis of late cardiac toxicity; assessment of %LVPWt, AT and ESS values in addition to standard echocardiographic examination could be the guidance for early diagnosis of late cardiac toxicity.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056475718

Download citation: RISBibTeXText

PMID: 20382616

DOI: 10.5152/akd.2010.042


Related references

Early diagnosis of anthracycline toxicity in asymptomatic long-term survivors: dobutamine stress echocardiography and tissue Doppler velocities in normal and abnormal myocardial wall motion. European Journal of Echocardiography 11(10): 814-822, 2011

Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer. Pediatrics International 48(3): 313-320, 2006

Low-dose dobutamine stress echocardiography in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. European Heart Journal 22(Abstract Supplement): 540, September, 2001

Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. Journal of the American College of Cardiology 19(2): 394-401, 1992

Low-dose dobutamine echo stress test for the evaluation of cardiac function in asymptomatic childhood cancer survivors treated years before with anthracycline. European Heart Journal 19(ABST SUPPL ): 312, 1998

Dobutamine stress echocardiography predicts cardiac events or death in asymptomatic patients long-term after heart transplantation: 4-year prospective evaluation. Journal of Heart and Lung Transplantation 23(11): 1238-1244, 2004

Dobutamine stress echocardiography predicts cardiac events or death in asymptomatic patients long-term after heart transplantation Four-years prospective evaluation. Circulation 106(19 Supplement): II 349, November 5, 2002

Cardiac stress imaging for the prediction of very long-term outcomes: Dobutamine stress echocardiography or dobutamine 99m Tc-sestamibi SPECT?. Journal of Nuclear Cardiology, 2016

Tissue and flow myocardial performance index measurements taken during dobutamine stress echocardiography for early diagnosis of late anthracycline cardiotoxicity. Pediatric Cardiology 31(1): 96-105, 2010

Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatric Research 39(3): 504-512, 1996

Optimizing long-term cardiac management after major vascular surgery: Role of beta-blocker therapy, clinical characteristics, and dobutamine stress echocardiography to optimize long-term cardiac management after major vascular surgery. Archives of Internal Medicine 163(18): 2230-2235, 2003

Dobutamine stress test in long term childhood cancer survivors treated with doxorubicin. Journal of the American College of Cardiology 17(2 SUPPL A): 333A, 1991

Value of negative dobutamine stress echocardiography in predicting long-term cardiac events. Journal of the American Society of Echocardiography 12(6): 471-475, 1999

Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia. Annals of Hematology 81(9): 504-507, 2002

Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy. American Journal of Cardiology 107(3): 472-477, 2011